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ABSTRACT
Motivation: Design a new computational tool allowing scientists
to functionally annotate newly discovered and public domain single
nucleotide polymorphisms in order to help in prioritizing targets in
further disease studies and large-scale genotyping projects.
Summary: SNPnexus database provides functional annotation for
both novel and public SNPs. Possible effects on the transcriptome
and proteome levels are characterized and reported from ﬁve major
annotation systems providing the most extensive information on
alternative splicing. Additional information on HapMap genotype
and allele frequency, overlaps with potential regulatory elements
or structural variations as well as related genetic diseases can
be also retrieved. The SNPnexus database has a user-friendly
web interface, providing single or batch query options using SNP
identiﬁersfromdbSNPaswellasgenomiclocationonclones,contigs
or chromosomes. Therefore, SNPnexus is the only database currently
providing a complete set of functional annotations of SNPs in public
databases and newly detected from sequencing projects. Hence,
we describe SNPnexus, provide details of the query options, the
annotation categories as well as biological examples of use.
Availability: The SNPnexus database is freely available at http://
www.snp-nexus.org.
Contact: claude.chelala@cancer.org.uk
1 INTRODUCTION
Single nucleotide polymorphisms (SNPs) are simple and very
commongeneticvariationsinasinglebaseofthefour-basesgenome
sequence. They represent a valuable resource for investigating the
genetic basis of diseases and are widely used for ﬁne-scale genetic
mapping and genome-wide association studies. It is well established
that certain SNPs may predispose to diseases such as diabetes and
cancer, as well as affecting disease progression. Based on linkage
analysisresultsand/orknowledgeaboutthediseasepathways,genes
areselectedforsequencingandscreeningfornovelSNPs.Variations
that might be functionally relevant, such as those that lead to amino
acids changes, affect splicing sites, are found in known regulatory
elements or in conserved non-coding sequences are priority targets
in disease studies and large-scale genotyping projects.
Functional annotation data for publicly known SNPs are scattered
across many different databases, redundant and far from complete.
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They include a limited set of information and no options to allow
functional annotations of newly detected SNP. When dealing with
novel SNPs, researchers are faced with exploring many different
data sources, deciding which one to use and manually assessing
the functional relevance of their variants before selecting the
subset to use in future disease genotyping studies. As a result, the
task of making a complete assessment of the potential functional
consequences of both novel and known SNPs from sequencing or
genome-wide association studies is difﬁcult and time consuming.
The lack of suitable user-friendly tools for assessing the full impact
of SNPs is evident from numerous publications where the potential
functional role of SNPs was not properly explored. This could
compromise the design and results of any further experimental
investigation.
Here, we present SNPnexus, a one-stop solution for novel and
publicly known SNPs functional annotation. SNPnexus allows
single or batch queries using dbSNP identiﬁers or SNP genomic
coordinates on clones, contigs as well as chromosomes. From our
experience, this is particularly needed to complete public SNP
annotations. Also, this is very helpful for researchers discovering
novel SNPs by using clones or contigs as a reference sequence in
their analysis of sequencing data.
Because it is well known that each gene prediction program has
its own limitations that often lead to different results, SNPnexus
computes a wide range of possible effects for SNPs through the
main gene annotation systems: NCBI RefSeq (Pruitt et al., 2007),
UCSC Known Genes (Hsu et al., 2006), Ensembl (Hubbard et al.,
2007), the Vertebrate Genome Annotation (VEGA) (Ashurst et al.,
2005) andAceView (Thierry-Mieg and Thierry-Mieg, 2006). While
most other tools and studies mainly focused on the effects of SNPs
based on NCBI RefSeq and/or Ensembl genes, SNPnexus offers for
the ﬁrst time the possibility of assessing additional possible roles
for SNPs through VEGA, UCSC and AceView annotations. The
NCBI RefSeq is a high-quality, manually curated gene set. While
the Ensembl gene prediction dataset is computationally derived at
the genome level, VEGA’s annotations are manually curated on
more limited regions. The UCSC set of predictions is moderately
conservative, based on data from RefSeq, GenBank (Benson et al.,
2005) and UniProt (Bairoch et al., 2005). The AceView gene
dataset is produced from public experimental cDNA sequences
from the same species. These gene annotation sets have different
prediction methods and therefore show different information on
alternative splicing. By integrating all these annotated datasets,
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SNPnexus gives the broadest view of the potential functional role
of SNPs. The functional annotations through SNPnexus are detailed
on the different isoforms and should be considered carefully in
any SNP experimental functional assay. Furthermore, SNPnexus
investigates any potential regulatory role by computing the overlaps
with regulatory elements such as conserved transcription factor
bindingsites(TFBS)(Wingenderetal.,2001),microRNA(miRNA)
(Grifﬁths-Jones, 2004; Grimson et al., 2007; Lewis et al., 2003,
2005; Weber, 2005) and promoter predictions (Davuluri et al.,
2001). SNPnexus summarizes any related information from genetic
association studies of complex diseases and disorders available
from the genetic association database (GAD) (Becker et al., 2004),
overlaps with genomic structural variability (Conrad et al., 2006;
Hinds et al., 2006; Iafrate et al., 2004; Locke et al., 2006; McCarroll
etal.,2006;Redonetal.,2006;Sebatetal.,2004;Sharpetal.,2005;
Tuzun et al., 2005), dbSNP (Sherry et al., 2001) as well as HapMap
(Frazer et al., 2007) genotype and allele frequency.
2 METHODS
SNPnexus architecture has two layers: an access layer with a web server and
a storage layer with a MySQL database server. We wrote a Perl annotation
pipeline to connect the user data to the source database and perform all the
calculationsdisplayedinthewebinterface.PrimarydatasourcesareEnsembl
and UCSC. We used the MySQL tables from the March 2006 GenBank
freeze assembled by NCBI (hg18, Build 36, http://hgdownload.cse.ucsc.edu/
goldenPath/hg18/database/) and EnsemblMart_48 (ftp://ftp.ensembl.org/
pub/release-48/mysql/ensembl_mart_48).TheGeneticAssociationDatabase
team provided the link to download GAD data ﬁle. miRBase data
were downloaded from the database FTP site (http://microrna.sanger.ac.
uk/sequences/ftp.shtml) Structural variability data were derived from the
Database of Genomic Variants (DGV) (http://projects.tcag.ca/variation/) via
UCSC. SNPnexus will be updated on a regular monthly basis.
3 RESULTS
3.1 Queries
Queries can be made in both single and batch mode (10000 SNPs).
Users can annotate a novel SNP by providing its position on the
genomic clone (clone, contig or chromosome), its alleles and strand.
This is particularly useful when SNPs are detected by sequencing
many DNA samples and aligning experimental results against a
partial clone, contig or chromosome reference sequence. Users can
also query SNPnexus for known SNPs by providing the rs# number.
This could be used when dealing with reassessment of the functional
role of HapMap and dbSNP variants, for example. SNPnexus query
options and annotation categories are presented in Figure 1.
3.2 Annotation categories and examples
3.2.1 Gene SNP consequences To the best of our knowledge,
SNPnexus is the only tool that provides a comprehensive overview
of potential functional consequences of SNPs on alternatively
splicedgenesbyexploringﬁvedifferenttranscriptomeandproteome
models: NCBI RefSeq (Pruitt et al., 2007), UCSC (Hsu et al., 2006),
Ensembl (Hubbard et al., 2007), VEGA (Ashurst et al., 2005) and
AceView (Thierry-Mieg and Thierry-Mieg, 2006). While the gene
annotation from NCBI RefSeq and Ensembl are widely used gene
reference systems, they do not properly reﬂect transcript variation
due to alternative splicing. The number of UCSC transcripts
Fig. 1. SNPnexus query options and annotation categories.
is56722,whichisalmostequaltothenumberofEnsembltranscripts
(56155) and double of the number for RefSeq (25078). VEGA
has over three times more transcript variants than RefSeq (88828).
Gene model in AceView provides more extensive analysis of
alternative splicing. Over the entire genome the number ofAceView
transcripts (258618) exceeds Ensembl and UCSC by a factor
of four, VEGA by a factor of three and RefSeq by a factor of
10. Potential effects of SNPs fall into seven categories: intronic,
5 UTR, 3 UTR, 5-upstream, 3-downstream, splicing site or coding
(synonymous or non-synonymous). For intronic SNPs, the distance
to the splicing site is reported. For coding SNPs, the coordinates
of the position within the cDNA, coding sequence (CDS), amino
acid as well as the peptide change produced (if any) are reported.
For 5-upstream and 3-downstream, a distance of 2 kb from the
UTR start or end is considered appropriate. As a ﬁrst example,
we explored the SNPs of DNA repair genes that were studied in
the context of overall survival of pancreatic cancer patients after
treatment (Li et al., 2007a). A strong effect of the polymerase β
(POLB) gene variants on overall survival was reported. Also, a
weak but signiﬁcant effect on overall survival was demonstrated for
8-oxo-guanine DNA glycosylase (hOGG1), apurinic/apyrimidinic
endonuclease I (APEX1) and X-ray repair cross-complementing
protein1(XRCC1)polymorphisms.Weconsideredallthevariantsin
these genes studied in the article (Table 1).The authors reported that
POLB A165G and T2133C variants were intronic with the dbSNP
reference rs2272615 and rs2953993, respectively. Also, the ﬁrst
variant of hOGG1 G2657A was intronic (rs293794) and the second
variant C315G was coding non-synonymous (S326C) or 3 UTR
(rs1052133). The APEX1 variant D148E (rs3136820) as well as
XRCC1 variants R194W (rs1799782) and Q399R (rs25487) were
coding non-synonymous. Using SNPnexus, we were able to assess
in details the functional consequences of these variants on each
isoformfromRefSeq,Ensembl,Vega,AceViewandUCSC.First,we
notedthathOGG1variantsoverlapwithisoformsoftheneighboring
gene calcium/calmodulin-dependent protein kinase I (CAMK1).
Similarly,APEX1 variant rs3136820 (ID used in the original paper,
currently merged to dbSNP rs1130409) could have a 5-upstream
effect on the neighboring gene O-sialoglycoprotein endopeptidase
(OSGEP) and 3-downstream effect on transmembrane protein 55B
(TMEM55B). We also found many additional potential regulatory
roles and coding non-synonymous changes leading to additional
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Table 1. SNP functional consequences
Panel A: as reported in previous studies
dbSNP Chrom Gene Functional consequences
rs293794 3 hOGG1 I
rs1052133 3 hOGG1 3 UTR, NS (S326C)
rs3136820 14 APEX1 NS (D148E)
rs2272615 8 POLB I
rs2953993 8 POLB I
rs1799782 19 XRCC1 NS (R194W)
rs25487 19 XRCC1 NS (Q399R)
rs2248690 3 AHSG Promoter
rs4918 3 AHSG Thr/Ser
rs1071592 3 AHSG Thr/Thr
Panel B: computed using SNPnexus
dbSNP Gene Source Transcripts Functional consequences [peptide shift (if any), number of transcripts]
rs293794 hOGG1 RefSeq 5
I
Ensembl 6
VEGA 6
UCSC 5
AceView 8
CAMK1 RefSeq 1 I (1)
Ensembl 2 I (2)
VEGA 2 I (2)
UCSC 3 I (2); 5up (1)
AceView 6 I (4); 5up (1); 5 UTR (1)
rs1052133 hOGG1 RefSeq 8 NS (S326C, P332A, 2); 3 UTR (1); I (5)
Ensembl 11 NS (S326C, P119A, P332A, 3); 3 UTR (1); I (6); 3down (1)
VEGA 9 NS (S326C, P332A, 3); I (6)
UCSC 11 NS (S326C, P332A, P97A, P41A, S91C, 5); I (5); 3’UTR (1)
AceView 19 NS (S326C, S115C, S42C, P98A, P103A, P332A, 6); I (8); 3 UTR (4); 3down (1)
CAMK1 RefSeq 1
3down
Ensembl 2
VEGA 2
UCSC 3
AceView 8
rs1130409 APEX1 RefSeq 3 NS (D148E, 3)
Ensembl 2 NS (D148E, 2)
VEGA 3 NS (D148E, 2); I (1)
UCSC 4 NS (D148E, 4)
AceView 22 NS (D148E, D124E, D130E, D131E, 13), I (4); 3 UTR (1); 5 UTR (1); 3down (3)
NP RefSeq –
Ensembl 1 I (1)
VEGA –
UCSC –
AceView –
OSGEP RefSeq 1
5up
Ensembl 1
VEGA 1
UCSC 1
AceView 5
TMEM55B RefSeq 2
3down
Ensembl 2
VEGA 2
UCSC 2
AceView 6
rs2272615 POLB RefSeq 1 I (1)
Ensembl 1 I (1)
(continued)
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Table 1. Continued
Panel B: computed using SNPnexus
dbSNP Gene Source Transcripts Functional consequences [peptide shift (if any), number of transcripts]
VEGA 5 I (5)
UCSC 2 I (2)
AceView 8 3 UTR (1); 3down (1); I (6)
rs2953993 POLB RefSeq 1 I (1)
Ensembl 1 I (1)
VEGA 6 I (5); 5up (1)
UCSC 2 I (2)
AceView 8 I (8)
rs1799782 XRCC1 RefSeq 1 NS (R194W, 1)
Ensembl 1 NS (R194W, 1)
VEGA 5 NS (R194W, R157W, 5)
UCSC 1 NS (R194W, 1)
AceView 9 NS (R30W, R89W, R157W, R169W, R213W, R219W, R273W, 7); 5 UTR (2)
rs25487 XRCC1 RefSeq 1 NS (Q399R, 1)
Ensembl 1 NS (Q399R, 1)
VEGA 5 NS (Q399R, 1); 3down (4)
UCSC 1 NS (Q399R, 1)
AceView 9 NS (R126G, Q181R, Q235R, Q332R, Q422R, Q478R, 6); 3down (3)
rs2248690 AHSG RefSeq 1
5up
Ensembl 1
VEGA 2
UCSC 4
AceView 8
rs4918 AHSG RefSeq 1 NS (S256T, 1)
Ensembl 1 NS (S256T, 1)
VEGA 4 NS (S256T, S255T, S9T, 3); 5 UTR (1)
UCSC 3 NS (S255T, S256T, S257T, 3)
AceView 7 NS (S219T, S228T, S255T, S256T, S257T, 5); 3down (2)
rs1071592 AHSG RefSeq 1 S (1)
Ensembl 1 S (1)
VEGA 4 NS (H6P, 1), S (2); 3down (1)
UCSC 3 S (3)
AceView 6 S (5); 3down (1)
I=intronic, 5up=5-upstream, 3down=3-downstream, NS=coding non-synonymous, S=coding synonymous.
amino acid changes (Table 1). We noted that these effects were
also missed in other papers where some of the variants were
investigated in additional cancers (Huang et al., 2007; Sangrajrang
etal.,2008).SNPnexusenableddiscoveryofnewpotentialfunctions
that should be considered in any further analysis. As a second
example, we considered the 2-Heremans-Schmid glycoprotein
(AHSG), a candidate for type 2 diabetes (T2D) susceptibility. Using
direct sequencing of the AHSG promoter region and exons, a
recent study identiﬁed nine common SNPs with a minor allele
frequency (MAF) >5%, assessed their consequences using NCBI
RefSeq AHSG mRNA sequence (NM_001622) and carried out a
detailed genetic association study of their contribution to the genetic
susceptibility of T2D in French Caucasians (Siddiq et al., 2005).
Their results showed that the major allele of a synonymous coding
SNP (rs1071592) presented signiﬁcant evidence of association with
T2D. Also, one promoter variant and one coding non-synonymous
variant (rs2248690 and rs4918) in strong linkage disequilibrium
(LD) with rs1071592 showed evidence-approaching signiﬁcance.
We reanalyzed the consequences of these three SNPs on all
AHSG transcripts using SNPnexus. We conﬁrmed the synonymous
coding consequence of rs1071592. However, we found that this
SNP can have additional 3-downstream and most importantly
synonymous non-coding (H6P) consequences (Table 1). For rs4918,
we conﬁrmed the non-synonymous coding S256T and found
additional potential effects. We conﬁrmed the promoter location
for the SNP rs2248690 in all transcripts annotations (Table 1).
Again, these novel potential functional roles should be included
in any experimental assay investigating the role of these variants
in T2D.
3.2.2 HapMap population data The HapMap Project provides
a resource of genotypic data of ∼4 million common SNPs in
lymphoblastoid cell lines derived from four human populations:
African YRI (from Yoruba in Ibadan, Nigeria), Japanese JPT
(from Tokyo, Japan), Han Chinese CHB (from Beijing, China) and
European CEU (from Utah, USA with ancestry from northern and
western Europe) (Frazer et al., 2007). The HapMap genotypic data
have proven to be a key resource for researchers investigating the
genetic contribution to human diseases, variation in gene expression
and drug response (Zhang et al., 2008). The HapMap data could
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be used to estimate MAF of SNPs in the different populations.
This is essential since common SNPs having a MAF value ≥5%
or 1% are mainly targeted in genetic studies. This hypothesis has
been challenged by studies reporting that rare variants may also
inﬂuencecommondiseases(Cohenetal.,2004;Romeoetal.,2007).
Rare SNPs might also be useful when the disease-causing variant is
also rare. An estimation of the MAF in the different populations
could also help in assessing the association between SNPs and
a given disease. SNPnexus provides both genotype and allele
information, count and frequency. If f(11), f(12) and f(22) are the
HapMapfrequenciesofthethreegenotypesatagivenlocuswithtwo
alleles (1 and 2), then the frequency p of allele 1 and the frequency
q of allele 2 are: p=f(11)+0.5× f(12) and q=f(22)+0.5×f(12).
MAF is simply the smaller of these two frequencies.As an example
of use, we considered the association between the +1858C>T SNP
(rs2476601) in PTPN22 and type 1 diabetes (T1D) that has been
reported in separate studies among different populations (Chelala
et al., 2007; Smyth et al., 2004). However, the +1858T allele was
not found in a large Asian cohort (Kawasaki et al., 2006), which
raises the possibility that rs2476601 is not associated with T1D in
Asianpopulations.Itisalsopossiblethatotherpotentiallyfunctional
variants in PTPN22 may be responsible for the susceptibility to
T1D in these populations or the PTPN22 locus contains another
functional variant in LD with rs2476601. When querying HapMap
data for rs2476601, SNPnexus conﬁrmed that the +1858T allele
was not present in the HapMap Asian populations but also showed
that the same hypothesis could apply for the African population
since the +1858T allele was not found in the HapMap Nigerian
population.
3.2.3 Regulatory elements SNPnexus can be queried against
any overlap with conserved TFBS (Wingender et al., 2001),
First-Exon promoter predictions (Davuluri et al., 2001) and
miRNA (Grifﬁths-Jones, 2004; Grimson et al., 2007; Lewis et al.,
2003, 2005; Weber, 2005). One could quickly investigate the
SNP putative phenotypic effect and prioritize analysis of SNPs
that disrupt TFBS relevant to the transcriptional pathways of
the disease of interest or the speciﬁc tumor subtype. As the
overlap with TFBSs is only putative, we made the prediction
more likely to be of biological importance by restricting the
Transfac Matrix Database (v7.0) TFBSs to those conserved
in the human/mouse/rat alignment (http://genome.ucsc.edu/cgi-
bin/hgTrackUi?g=tfbsConsSites). Promoter polymorphisms that
could alter gene expression can be also investigated using
SNPnexus. Overlaps are checked against the FirstEF (First-Exon
Finder), a 5 -terminal exon and promoter prediction program.
Also, one could investigate if a particular SNP of interest is
a potential miRSNP occurring in putative miRNA target sites
and hence could interfere in miRNA-mediated gene regulation.
miRNAs bind to target sites in the 3 UTR region of mRNA and
act as repressors of protein-coding genes or activators of RNA
degradation. Aberrant expression of miRNAs may be involved in
human diseases, including cancer. As an example, we chose the
B-cell translocation gene-2 (BTG2), a potential target of cellular
miRNAs with deregulated expression in breast cancer (Kawakubo
etal.,2004;YoonandDeMicheli,2005).WeinvestigatedifanySNP
overlap with miRNAs that target BTG2 and thus could play a role in
the aberrant regulation of BTG2 expression in breast carcinoma. We
used SNPnexus with BTG2 SNPs as input and searched for overlaps
with miRNA. SNPnexus prioritized BTG2 miRSNP rs1804734
showingthatitoverlapswithtargetscanBTG2:miR-21.Addedtothe
fact that miR-21 was reported to be upregulated in breast cancer
(Iorio et al., 2005), the role of rs1804734 in breast cancer is worthy
of investigation to see whether it could interfere with BTG2:miR-21
processing, expression and/or binding to target BTG2 mRNA.
3.2.4 Genetic association database GAD is an archive of
published scientiﬁc papers on human genetic association studies
of complex diseases and disorders (Becker et al., 2004). When
investigating the role of variants, the user can mine GADand extract
any related information related to the gene of interest.
3.2.5 Structural variability Human DNA-level variation ranges
from bi-allelic SNPs to large-scale structural variation [such as
deletions, duplications, insertions, inversions and large-scale copy-
number variants (CNVs) also called copy-number polymorphisms
(CNPs)]. Structural variants can have a direct effect on gene dosage
or an indirect effect on expression of a gene by changing its
position on the genome (Feuk et al., 2006). They can predispose to
additional damaging structural changes or function as susceptibility
alleles in complex genetic diseases (Feuk et al., 2006). A recent
study showed the importance of CNVs in complex phenotypes,
and the need to assess it independently from SNPs (Stranger
et al., 2007). Also, the analysis of SNPs within genes with CNV
could be technically challenging. Furthermore, it is important
to distinguish abnormal genetic lesions from normal CNP since
some of the genetic differences in tumor genomes when analyzed
in comparison to an unrelated normal genome could be due to
germline CNPs. SNPnexus allows integration of both types of
variation and assessment of the hypothesis cited above. This could
be useful for genes and SNPs located within a CNV. In this
case, both gene copy number and the genotyping of relevant
SNPs should be investigated in order to understand the phenotypic
impact of genome variation on the disease of interest. SNPnexus
assesses overlaps with putative CNPs and sites of intermediate-
sized structural variation (ISV) determined by various methods.
This covers deletions from genotype analysis using the HapMap
Phase I data, release 16a (McCarroll et al., 2006), HapMap Phase I
data, release 16c.1, CEU andYRI samples (Conrad et al., 2006) and
from haploid hybridization analysis in 24 unrelated individuals from
the Polymorphism Discovery Resource, selected for SNP LD study
(Hinds et al., 2006). This also include CNP from BAC microarray
analysis in a ﬁrst population of 55 individuals (Iafrate et al., 2004),
a second population of 47 individuals (Sharp et al., 2005) as well
as in the HapMap Phase II data (Redon et al., 2006). Further CNP
regions are identiﬁed using array CGH in the HapMap populations
(269 individuals) (Locke et al., 2006) and using representational
oligonucleotide microarray analysis (ROMA) in a population of 20
normal individuals (Sebat et al., 2004). ISV sites are detected by
mapping paired-end sequences from a human fosmid DNA library
(Tuzun et al., 2005). As an example, we reused AHSG SNPs
rs1071592, rs2248690 and rs4918 (Table 1). SNPnexus found an
overlap with a CNV region thus suggesting that the genotypes of
rs1071592 and rs4918 as well as the overlapping CNV should both
be investigated in order to understand the phenotypic impact of
these genome variations on T2D in French Caucasians. Similarly,
rs2476601 in PTPN22 overlaps with a CNV that should be also
studied in T1D.
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4 DISCUSSION AND CONCLUSION
Both focused candidate-gene and whole-genome studies require the
selection of an optimal number of tagSNPs. This is an important,
challenging task that will affect the study outcome and cost,
especially for complex diseases where the number of candidate
genes is expected to be large. SNPnexus could help in the selection
of tagSNPs with potential functional effect, which could be used
to complement the selection based on the haplotype information
and therefore increase the sensitivity and efﬁciency of large-scale
genotyping projects (Jorgenson and Witte, 2006; Wiltshire et al.,
2006).
SNPnexusisthemostcomprehensiveresourcecurrentlyavailable
for assessing the functional consequences of novel and public
domain SNPs on the major transcriptome, proteome, regulatory
and structural variation models. We provide examples on how it
allows researchers, through a user-friendly web interface, to work
onnovelandpubliclyavailableSNPstoextractimportantannotation
and genotyping information. SNPnexus data should be considered
in the design of experimental functional assays so as to prioritize
the list of SNPs or CNVs to be investigated in further association
studies.
To the best of our knowledge, there are no tools or databases that
provide the same information as SNPnexus. Therefore, we can only
reviewothertoolstoprovideanevaluationofoursystem.SNPnexus
has a gene/protein annotation category allowing the users to view
and navigate through large sets of high-dimensional data from
ﬁve major annotation systems (Ensembl, RefSeq, VEGA,AceView,
UCSC). Out of these, only Ensembl is mainly used by other tools,
such as PupaSNP (Conde et al., 2006) and SNAP (Li et al., 2007b).
SNPnexus offers more query options than PolyPhen (Ramensky
et al., 2002) and SNAP. While these tools in their current versions
allow queries for one SNP at a time, SNPnexus allows single and
batchqueries.Mostimportantly,SNPnexusistheonlytoolproviding
annotations for novel and publicly known SNPs, while all other
toolsfocusonalreadyknownvariantsfromdbSNP.Thus,SNPnexus
is complementary to existing tools, such as Polyphen, SNAP and
PupaSNP by allowing researchers to connect novel annotated SNPs
to these tools. One could get further functional annotation of non-
synonymous SNPs using PolyPhen, SNPs that disrupt exon splicing
enhancers using PupaSNPs or redesign PCR primers to re-sequence
individual variants using SNAP.
The recent technological advances in next-generation sequencing
enable comprehensive screening of genome variation. One of the
main promises and challenges lies with the analysis of these
variationsandtheselectionofthosewhocontributetothephenotype.
Although designed initially to annotate novel SNPs from candidate
gene sequencing studies, SNPnexus query option for novel SNPs
could also be used to assess the potential signiﬁcance of candidate
variants detected by next-generation sequencing, point to the
gene/protein isoform that might be phenotypically important and
guide future experimentation. SNPnexus is freely available and
will be updated regularly. We welcome feedback from the user
community on new annotation systems that could be added to
SNPnexus.
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